Colorectal cancer (CRC) is amongst the leading causes of cancer-related mortality worldwide. Emerging evidence suggests that human cytomegalovirus (HCMV) exists in the tumour tissue of CRC and is associated with disease outcome. To study whether tumoral HCMV is related to viral reactivation in blood, tumour specimens and pre-and post-operative blood samples from CRC patients were collected prospectively. PCR and quantitative PCR were performed to detect HCMV DNA. HCMV IgG and IgM antibodies were measured using a microparticle enzyme immunoassay. Transcription of a spliced HCMV UL73 gene transcript was analysed by quantitative reverse transcription PCR. HCMV was detected in 42.2 % (35/83) of the tumour samples, with a low median viral load (30.08, range 2.33-5704 copies per 500 ng genomic DNA). The vast majority (80/81, 98.8 %) of the CRC patients were seropositive for HCMV IgG. HCMV DNA was positive in 11.3 % (22/194) of the pre-operative and 8.9 % (15/168) of the post-operative blood samples. However, presence of HCMV and its viral load in tumours were not associated with the detection or viral loads in blood samples. About 26.67 % (8/30) of the HCMV-positive tumours with available RNA had detectable viral UL73 transcripts, whilst none of the blood samples were positive for viral RNA (P,0.0001). Therefore, presence of HCMV in tumours does not correlate with the serological or viraemic status of CRC patients. Active viral gene transcription occurred in the tumour but not in the blood of CRC patients. HCMV reactivation in CRC patients is possibly due to virus-cancer interactions in the CRC tumour microenvironment.
INTRODUCTION
Human cytomegalovirus (HCMV) ubiquitously infects the human population. Following primary infection, the virus establishes a life-long persistent infection in the host and reactivates when the host immune system is suppressed. In immunocompromised hosts, HCMV causes severe and even fatal complications, including retinitis, pneumonitis, colitis and encephalitis (Fisher, 2009; Ives, 1997) . In healthy individuals, however, the virus resides latently in myeloid progenitor cells of the peripheral blood with occasional asymptomatic reactivation (Reeves & Sinclair, 2008) .
The relationship between HCMV infection and cancer has been investigated for decades. In vitro studies have suggested that HCMV transforms cells, increases tumorigenicity in mice and contributes to oncogenesis, presumably through the 'hit-and-run' mechanism (Geder et al., 1976 (Geder et al., , 1978 Shen et al., 1997) . In recent years, the 'oncomodulatory' role of HCMV has been increasingly recognized because of its ability to modulate the malignant properties of cancer cells (Michaelis et al., 2009) . Through complex and as-yet unidentified mechanisms, HCMV influences cell proliferation, cancer invasiveness, angiogenic factors and anti-tumour immune responses in the tumour microenvironment (Blaheta et al., 2004; Caposio et al., 2011) . In brain cancer cases, there is mounting evidence for the oncomodulatory effects of HCMV. The virus has been found to interact with key signalling pathways and act as a promoter in glioma pathogenesis (Cobbs, 2011) . Supporting data came from clinical studies demonstrating that treatment with an antiviral agent significantly increased the survival rate of glioma patients, suggesting a possible pivotal role of HCMV in oncomodulation of brain tumours (Söderberg-Nauclér et al., 2013; Stragliotto et al., 2013) .
The association between HCMV and colorectal cancer (CRC) has been suggested by a number of studies that identified HCMV in the tumour tissues of CRC patients (Dimberg et al., 2013; Harkins et al., 2002; Huang & Roche, 1978) . A clinical analysis demonstrated unfavourable outcomes in elderly CRC patients with HCMV present in tumours (Chen et al., 2014) . In CRC, the nucleic acids of HCMV have been found to specifically localize to the neoplastic mucosal epithelium, but not the submucosa, stroma or immune cells that infiltrate the tumour tissue (Chen et al., 2012) . Such observations raise the question of whether HCMV presence in tumours is determined by characteristics of the tumour microenvironment or whether it is part of the generalized reactivation of the virus in the bloodstream. During latency, HCMV stays dormant in monocytes of the peripheral blood (Sinclair & Sissons, 2006) . The virus actively replicates and releases viral particles to the bloodstream when host immunity is suppressed. As only 40 % of CRC tumours are positive for HCMV, the question arises as to whether patients with HCMV-positive tumours have a higher seroprevalence of antibody against the virus or, instead, they have a more compromised antiviral immune response resulting in more frequent reactivation of HCMV in the blood.
In order to investigate HCMV seroprevalence and to compare virus replication between blood and tumour tissues, we prospectively collected blood and tumour samples from 83 CRC patients over a period of 1 year. Patients with HCMV-positive and HCMV-negative tumours were compared to demonstrate differences. Here, we show that reactivation of HCMV is probably a localized event in the tumour microenvironment of CRC patients and that it does not correlate with the viral life cycle in the bloodstream.
RESULTS

Detection of HCMV in tumour specimens of CRC patients by PCR
Between January 2011 and February 2012, a total of 109 patients were screened for CRC. Twenty-six patients were excluded because their final diagnosis was not CRC (13 patients), the patients did not undergo surgery (four patients) or because the patients did not consent to participation in the study (nine patients) (Fig. 1) . Tumour specimens were collected from 83 CRC patients. HCMV was detected in 35 (42.2 %) of the tumour samples by PCR. The demographic characteristics and underlying diseases of patients are listed in Table 1 .
Pre-and post-operative HCMV antibodies in CRC patients
Amongst the CRC patients from whom blood samples were obtained, the vast majority (80/81, 98.8 %; with HCMV-positive tumours and one (1/44, 2.2 %) patient with an HCMV-negative tumour. After surgery, the percentages of HCMV IgG or IgM seropositivity did not change, and seropositivity did not differ between patients with HCMV-positive or HCMV-negative tumours. The serum levels of pre-and post-operative HCMV IgG were not different between patients with HCMV-positive or HCMVnegative tumours, although in both groups of patients the HCMV IgG levels decreased slightly after surgery.
Detection of HCMV viral loads and UL73 transcripts in tumours and blood samples of CRC patients
Low-level viral loads were detected in tumours that were positive for HCMV by PCR (median 30.08, range 2.33-5704 copies per 500 ng genomic DNA; (Fig. 2a) .
Pre-and post-operative blood samples were collected to detect HCMV DNA and viral UL73 transcripts. A total of 194 pre-operative and 168 post-operative blood samples were collected, including 180 plasma (96 pre-operative and 84 post-operative), 179 buffy coat (95 pre-operative and 84 post-operative) and three serum (pre-operative) samples. Amongst these samples, 11.3 % (22/194) of the pre-operative and 8.9 % (15/168) of the post-operative blood samples were positive for HCMV DNA. The percentage of blood specimens that was PCR-positive was significantly lower than that of the tumour specimens (Fig. 3) . 
Human cytomegalovirus and colorectal cancer
The median viral loads were 486 (range 169.8-8964) copies ml 21 in the pre-operative blood and 752 (range 10.9-2124) copies ml 21 in the post-operative blood. Neither pre-nor post-operative blood from CRC patients contained detectable viral UL73 transcripts (Fig. 2b, c) .
We then analysed the blood HCMV status according to the presence or absence of HCMV in tumours. For patients whose tumours were positive for HCMV DNA, 14.7 % (10/68; Fig. 4a ) of the pre-operative blood samples also contained detectable HCMV DNA, with a median viral load of 655 (range 248-2170) copies ml 21 (Fig. 4b) . A slightly lower percentage (9.5 %, 12/126) of HCMV DNA-positive blood samples and similar viral loads in preoperative blood samples (median 806, range 169.8-8964 copies ml 21 ) were found in patients with HCMV-negative tumours. In post-operative blood samples, HCMV DNA was detected in 11.3 % (7/62) of patients with HCMVpositive tumours and 7.5 % (8/106) of patients with HCMV-negative tumours. The median viral load of post-operative blood specimens was 1052 (296-2124) copies ml 21 in patients with HCMV-positive tumours and was slightly lower (median 503, range 10.9-1604 copies ml 21 ) in patients with HCMV-negative tumours.
DISCUSSION
The results of this study revealed that regardless of whether HCMV DNA was present or absent in CRC tumour tissues of CRC patients, the vast majority of these patients were chronically infected with HCMV, as reflected in the nearly 100 % seroprevalence of HCMV antibody in both groups of patients. Using a sensitive quantitative realtime PCR method, we demonstrated that the status of viral replication in the blood did not correlate with the presence or absence of HCMV DNA in tumours. Importantly, active transcription of a viral gene was found in the tumour tissues of CRC patients, but not their peripheral blood.
The rate of HCMV-positive blood samples of CRC patients was similar to that previously reported in patients with solid tumours and non-haematologic diseases (with an 8.5 % antigenaemia rate) (Han, 2007) . The similar frequencies of HCMV DNA detection and levels of viraemia in H.-P. Chen and others patients with both HCMV-positive and HCMV-negative tumours provided further insight into the pathophysiology of both HCMV infection and CRC. These results suggest that, for CRC patients, tumoral HCMV presence is probably a localized phenomenon determined primarily by factors in the tumour microenvironment. HCMV reactivation is usually accompanied by detectable viraemia (Chemaly et al., 2005; Gandhi & Khanna, 2004; Sinclair & Sissons, 2006) . Viraemia, however, is not mandatory for HCMV to cause end-organ diseases; localized immune compromise is sufficient for the virus to reactivate in specific tissues (Saga et al., 2007) . In CRC, the immunological microenvironment of tumours plays a critical role in cancer development and progression (Galon et al., 2006) , and both innate and adaptive immunity are suppressed in the tumour microenvironment (Evans et al., 2006) . A reasonable speculation is that HCMV is brought through the bloodstream to the tumour tissue, where a suppressed immunity supports viral reactivation. Another contrary, yet more possible, mechanism is that the inflammatory milieu in the tumour microenvironment actually drives viral reactivation, as HCMV tends to reactivate when myeloid progenitors and dendritic cells undergo differentiation (Hahn et al., 1998) . Viruses in the tumour microenvironment may reactivate following cell differentiation and subsequently infect the cancerous mucosal epithelium.
Another important finding of this study is that active viral gene transcription is occurring in the tumour tissue of CRC patients. It is noteworthy that none of the 362 pre-or postoperative blood samples from CRC patients contained detectable viral transcripts. Such a finding further supports the speculation that HCMV replication in CRC is a localized event in the tumour microenvironment, independent of the virus life cycle in the bloodstream. To prevent DNA contamination in qRT-PCR, the TaqMan qRT-PCR probe was designed to target the junction of the spliced exons of UL73, thus providing unequivocal evidence of viral gene transcription. The HCMV UL73 gene is highly conserved amongst members of the family Herpesviridae and encodes the envelope glycoprotein gpUL73 (gN). Together with another glycoprotein, gpUL100 (gM), the gM-gN complex is able to induce neutralizing antibodies in the host and hypothetically plays a role in HCMV immunopathogenesis (Dal Monte et al., 2001; Mach et al., 2000) . We speculated that such a virus-encoded immunomodulatory gene might play a role in the immune microenvironment of CRC tumours. A comprehensive survey is needed to determine the transcription profiles of these genes in the tumour tissue of CRC patients.
There are limitations of this study. One limitation is that we did not have blood samples from healthy individuals without cancer or patients with other types of cancers for comparison. The blood HCMV status may differ between different populations of patients. The other limitation is that almost all of the patients in the present study, either with or without HCMV present in their tumours, were seropositive for HCMV IgG, suggesting a nearly 100 % chronic, latent HCMV infection in these patients. In a recent study of glioma, *30 % of the patients were seronegative for HCMV, despite the detection of viral nucleic acids and proteins in tumour specimens (Rahbar et al., 2015) . Further investigation is needed to clarify whether HCMV exists in tumours of HCMV-seronegative CRC patients.
CONCLUSION
The results of this study indicate that the presence of HCMV in tumours did not correlate with the serological or viraemic status of CRC patients. Active viral gene transcription occurred in the tumour but not in the blood of CRC patients. Reactivation of HCMV in CRC patients may result from virus-cancer interactions in the CRC tumour microenvironment, but not be generalized to reactivation in the blood.
METHODS
Study population and specimens. This study was approved by the Institutional Review Board of Taipei Veterans General Hospital (VGHTPE) and written informed consent was obtained from all participants. Patients who underwent surgical resection for CRC between January 2011 and February 2012 were included in this prospective cohort study. The criteria for inclusion in the study were patients aged 20 years or older, with malignant tumour(s) of the colon or rectum, who gave informed consent to participate. Patients were excluded if they were younger than 20 years of age, or pregnant, did not have pathological proof of CRC or had immunocompromised conditions, including neutropenia v500 mm 23 , organ transplantation and human immunodeficiency virus infection.
Surgically resected CRC specimens were stored at 270 uC in the bank of residual surgical tissues of the Colon and Rectal Surgery Division, VGHTPE. To maintain the quality of RNA and DNA, a research assistant immediately took the resected specimen into RNA later solution (Sigma-Aldrich) once the primary tumour was excised. Peripheral blood was sampled from CRC patients before and after surgery. Between 5 and 10 ml of their blood was collected into an EDTA-containing tube and then centrifuged at room temperature for 10 min at 760 g. The plasma in the upper layer was collected and stored at 280 uC. The remaining fraction of each blood sample was mixed with equal volumes of PBS and Ficoll-Paque (GE Healthcare Lifescience), and centrifuged at room temperature for 10 min at 620 g. The buffy coats containing PBMCs were collected and stored at 280 uC until use.
Extraction of DNA and mRNA, and RT. Pre-and post-operative blood samples, including plasma, buffy coat and serum samples, were collected from patients with CRC. Viral DNA and RNA were extracted from using a QIAamp Viral RNA/DNA kit (Qiagen) according to the manufacturer's instructions. Tumour tissues from CRC patients were homogenized, and DNA and RNA were extracted with a DNA Mini kit and an RNeasy Mini kit, respectively (Qiagen). The quality and quantity of DNA was confirmed using a NanoDrop 1000 spectrophotometer. The quality of RNA was examined by capillary electrophoresis and estimated by RNA integrity number (RIN). An RIN w7 was required for all specimens. The DNA and RNA extracts were stored at 280 uC. RNA was reverse transcribed with an ABI High Capacity cDNA Reverse Transcription kit (Life Technologies). The cDNA was stored at 220 uC until use.
PCR of the HCMV UL55 and UL144 genes. To detect HCMV, previously published primers were adopted to amplify the viral genes UL55 and UL144 (Chen et al., 2012) . The reaction mixture contained 1| PCR buffer, 500 mM dNTP mixture, 1.5 mM Mg 2+ , 300 nM primer mix, 0.025 U (UL144 PCR) or 1.25 U (for UL55 PCR) Taq DNA polymerase (Invitrogen) and 2 ml sample DNA. The final volume of the reaction mixture was 20 ml. Forty-five PCR cycles were carried out for UL144 (95 uC, 1.5 min; 55 uC, 2 min; 72 uC, 1 min; with an initial temperature of 95 uC for 6 min and a final 7 min at 72 uC) and 40 cycles for UL55 (95 uC, 1.5 min; 55 uC, 2 min; 72 uC, 2 min; with an initial temperature of 95 uC for 5 min and a final 10 min at 72 uC) using a Perkin-Elmer thermal cycler (GeneAmp PCR system 9600; Applied Biosystems). The products were then electrophoresed on a 1.5 % agarose gel, stained with ethidium bromide and photographed under UV light.
Quantitative PCR of the HCMV UL73 gene. A plasmid containing one copy of the UL73 target sequence was constructed and transformed into ECOS 101 competent cells (Yeastern Biotech) to generate the plasmid standard. After overnight incubation at 37 uC, the plasmid concentration was determined. The corresponding copy number was calculated and 10-fold serial dilutions were made from 10 5 to 1 copy ml 21 to generate the standards.
To amplify UL73, primers and a TaqMan fluorogenic probe were designed using a commercial service (Assay by Design; Applied Biosystems) based on the HCMV strain AD169 sequence (GenBank accession number NC_001347): forward primer UL73-C-F (59-CCTGGTGGACTATGCTTAATGGCT-39), reverse primer UL73-C-R (59-GGAAGCAGCAATGTCGTAGTACAAT-39) and TaqMan minor groove binder (MBG) probe (59-ATTCTCATGGGAGCTTTT-39) carrying a 59 FAM (6-carboxy-fluorescein) reporter dye and a 39 quencher dye. Real-time PCR was carried out using the ABI PRISM 7000 Sequence Detection System and ABI TaqMan PCR Master Mix kit (Applied Biosystems). In brief, 5 ml extracted genomic DNA or UL73 plasmid DNA control, at a concentration of 100 ng ml 21 , was added to a real-time PCR mixture containing 10 ml 2| TaqMan Master Mix (ABI), 300 nM each primer, 200 nM fluorogenic probe and 0.4 ml 50| ROX reference dye. The final volume was 20 ml. PCR was carried out with initial uracil-N-glycosylase activation at 50 uC for 2 min, followed by 45 cycles of denaturation at 95 uC for 15 s and annealing/extension at 60 uC for 1 min. The number of UL73 copies was deduced from the threshold cycle values corresponding to the cycle number at which the released fluorescence exceeded 20 times the standard deviation of the mean baseline emission.
Quantitative detection of viral UL73/74 transcripts in CRC tumour samples. Viral RNA was extracted using a commercial kit (Qiagen). A TaqMan in-house qRT-PCR was developed to detect spliced UL73/74 transcripts. Primers (UL73/74 S-F: 59-GCTATTGA-GGGTGGACAGATTTACA-39, UL73/74 S-R: 59-CAGGCAAGCCA-AACCACAAG-39) and a probe (59-CTCCTCCTCCCCGCCGGA-39) were designed to amplify a 97 bp segment spanning the UL73/74 exon junction. The reaction mixture contained 10 ml 2| TaqMan Master Mix (Applied Biosystems), 300 nM primer mix, 200 nM probe and 5 ml RNA extract. The reaction started with RT at 48 uC for 30 min, followed by 45 cycles of denaturation at 95 uC for 15 s and annealing/extension at 60 uC for 1 min.
Quantitative detection of HCMV antibodies in blood. IgG and IgM antibodies against HCMV were measured by a microparticle enzyme immunoassay on the Abbott AxSYM system (Abbott Laboratories) according to the manufacturer's instructions. A cut-off value of 9 arbitrary units ml 21 was used to determine the seropositivity of HCMV antibody.
Statistical analysis. The x 2 test with Yates' correction or Fisher's exact test was used to compare differences in discrete variables. Continuous variables were compared using the Mann-Whitney Utest for data that did not follow a normal distribution. All analyses were performed with SPSS version 12 (SPSS Institute). Pv0.05 was considered statistically significant.
